Malignant bronchial carcinoid tumor metastatic to the pituitary in a thyroid carcinoma patient: Successful treatment with surgery, radiotherapy and somatostatin analog

Pituitary

Volumn 7, Issue 1, 2004, Pages 51-57

  Shimon, Ilan ^a   Hadani, Moshe ^a   Nass, Dvora ^a   Zwas, S Tzila ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Carcinoid; Octreotide; Papillary thyroid carcinoma; Pituitary metastasis

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANGIOPEPTIN; IODINE 131; LEVOTHYROXINE; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; PERTECHNETIC ACID TC 99M; PREDNISONE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN;

ADULT; ARTICLE; BRONCHUS CARCINOID; CANCER PATIENT; CASE REPORT; HEMIANOPIA; HUMAN; HYPOPHYSIS TUMOR; HYPOPITUITARISM; LUNG RESECTION; MALE; METASTASIS POTENTIAL; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID SCINTISCANNING; THYROIDECTOMY; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME; URINARY EXCRETION; VISUAL IMPAIRMENT;

BRAIN; BRONCHIAL NEOPLASMS; CARCINOID TUMOR; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 5644238516     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PITU.0000044627.63261.b4     Document Type: Article

References (21)

1. Max MB, Deck MDF, Rottenberg DA. Pituitary metastasis: Incidence in cancer patients and clinical differentiation from pituitary adenoma. Neurology 1981;31:998-1002.
2. Tumiati MN, Facchi E, Gatti C, Bossi A, Longari V. Scintigraphic assessment of pituitary adenomas and several diseases by indium-111-pentetreotide. Q J Nucl Med 1995;39(4 Suppl 1):98-100.
3. Masiukiewicz US, Nakchbandi IA, Stewart AF, Inzucchi SE. Papillary thyroid carcinoma metastatic to the pituitary gland. Thyroid 1999 9:1023-1027.
4. Bell CD, Kovacs K, Horvath E, Smythe H, Asa S. Papillary carcinoma of thyroid metastatic to the pituitary gland. Arch Pathol Lab Med 2001;125:935-938.
5. Sziklas JJ, Mathews J, Spencer RP, Rosenberg RJ, Ergin MT, Bower BF. Thyroid carcinoma metastatic to pituitary. J Nucl Med 1985;26:1097.
6. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: A review. Appl Immunohistochem Mol Morphol 2002;10:97-102.
7. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: A critical evaluation of new antibodies. J Clin Pathol 2002;55:662-668.
8. Srodon M, Westra WH. Immunohistochemical staining for thyroid transcription factor-1: A helpful aid in discerning primary site of tumor origin in patients with brain metastases. Hum Pathol 2002 ;33:642-645.
9. Oliveira AM, Tazelaar HD, Myers JL, Erickson LA, Lloyd RV. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol 2001;25:815-819.
10. Cai YC, Banner B, Glickman J, Odze RD. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum Pathol 2002;32:1087-1093.
11. Runder EJ, Lentz C, Brown J. Bronchial carcinoid tumor with skin metastases. Arch Dermatol 1965;92:73-75.
12. Patchell RA, Posner JB. Neurologic complications of carcinoid. Neurology 1986;36:745-749.
13. Rossi ML, Bevan JS, Fleming KA, Cruz-Sanchez F. Pituitary metastasis from malignant bronchial carcinoid. Tumori 1988;74:101-105.
14. Huang MC, Lee LS, Ho DM, Cheng H, Chung WY, Huang CI, Hsiao CY, Pan DH. A metastatic pituitary carcinoid tumor successfully treated with gamma knife radiosurgery. Zhonghua Yi Xue Za Zhi (Taipei) 2001 ;64:414-418.
15. Abe T, Matsumoto K, Lida M, Hayashi M, Sanno N, Osamura Y. Malignant carcinoid tumor of the anterior mediastinum metastasis to a prolactin-secreting pituitary adenoma: A case report. Surg Neurol 1997;48:389-394.
16. O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouche O, Catus F, Blumberg J, Ruszniewski P. Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000 ;88:770-776.
17. Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg 2002;21:913-917.
18. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990 323:1246-1249.
19. 1] octreotide scintigraphy in patients with carcinoid tumours: The predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994;131:577-581.
20. Shi W, Buchanan KD, Johnston CF, Larkin C, Ong YL, Ferguson R, Laird J. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumors correlate with responsiveness to somatostatin analogue treatment. Clin Endocrinol 1998;48:303-309.
21. Oberg K. Carcinoid tumors: Molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 2002;14:38-45.